A Phase 1 Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 16 Jul 2014 Planned End Date changed from 1 Jan 2015 to 1 Sep 2014, according to the ClinicalTrials.gov record.